FARN:LON
Faron Pharmaceuticals Oy
37,00 GBX
arrow_upward
+1,37%(+0,50) 1 zi
1 oct., 09:33:12 GMT+1 · GBX
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru FARN...
Deschide
37,75 GBX
Mare
37,75 GBX
Mic
37,00 GBX
Capitalizarea bursieră
75,00 mil.
Volum mediu
49,09 K
Volum
8,77 K
Prețul ridicat pe 52 de săptămâni
193,58 GBX
Prețul redus pe 52 de săptămâni
34,00 GBX
Rezultatul pe acțiune
-0,10 GBX
Acțiuni aflate în circulație
31,03 mil.
Nr. de angajați
36
Deschide
37,75 GBX
Mare
37,75 GBX
Mic
37,00 GBX
Capitalizarea bursieră
75,00 mil.
Volum mediu
49,09 K
Volum
8,77 K
Prețul ridicat pe 52 de săptămâni
193,58 GBX
Prețul redus pe 52 de săptămâni
34,00 GBX
Rezultatul pe acțiune
-0,10 GBX
Acțiuni aflate în circulație
31,03 mil.
Nr. de angajați
36
Subiecte de știri
Din surse web și de la parteneri de știri
Yahoo! Finance Canada
·
acum 3 ore
Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Despre Faron Pharmaceuticals Oy